A Blinded, Randomized Phase 2 Study of Troriluzole in Combination With Ipilimumab and Nivolumab in Patients With Melanoma Brain Metastases Previously Treated With Anti-PD-1 Therapy
Latest Information Update: 19 Dec 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Troriluzole (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 22 Nov 2023 Status changed from suspended to discontinued.
- 18 Nov 2022 Status changed from recruiting to suspended.
- 17 Sep 2021 Status changed from not yet recruiting to recruiting.